Medical & Research

Our membership often requests information on medical and research issues that may impact individuals with Down Syndrome and their families. As a result and in support of our organization's goal to "provide accurate and current information, resources, and support for people with Down syndrome, their families, and the community," we are passing along this information to assist our families in educating themselves about current medical and research initiatives. The Down Syndrome Guild of Dallas believes by providing this information, each family will be able to make decisions based upon their personal beliefs and situation. The information presented does not necessarily express the views of the Down Syndrome Guild and its distribution is intended to inform and not influence our readership.

  • UT Southwestern Down Syndrome Trial and Research Update
    Sat, January 17, 2015

    10:00 am - 11:30 am
    St. Monica's Catholic Church
    9933 Midway Rd
    Dallas, TX 75220

    Dr. Matt Byerly of UT Southwestern and Down syndrome advocate Paul Watson will provide an update on progress in Down syndrome medical research to improve memory and learning. Dr. Byerly will update us on the Roche Pharmaceuticals Down syndrome trial that he led in DFW last year. He will go on to discuss UT Southwestern's new Down syndrome research project starting in January. This project is a groundbreaking pilot study that will begin treatment during pregnancy for mothers pregnant with a baby with Down syndrome, and continue to treat the child through age 2. It is believed that the medication will improve early learning and memory as well as help the child's brain develop in a more typical fashion. The medication has a long track record of safe human use, and 7 studies in Down syndrome mice have shown it both safe and effective. Paul Watson will wrap up with an overview of current Down syndrome cognitive research progress in the US and internationally.

    Dr. Byerly has served as a member of the Food and Drug Administration Psychopharmacologic Drugs Advisory Committee. In 2012, Dr. Byerly joined the UT Southwestern Center for Autism and Developmental Disabilities (CADD), extending his research interest to studying potential pharmacologic treatments for neurodevelopmental disorders. He and colleagues are working to translate recent advances in the treatment of mouse models of fragile X syndrome and Down syndrome to individuals with these conditions. Paul Watson is a parent of a 13 year old with Down syndrome and has led state wide advocacy in special education, employment for those with intellectual disabilities, and Down syndrome medical research efforts.

    If you are interested in attending this seminar, please RSVP to Victoria Smith at (214) 267-1374 or victoria@downsyndromedallas.org no later than Wednesday, January 14, 2015. Childcare is not provided.



For Medical Professionals